Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Sectoral/ Thematic median (252 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 03 Apr 2006 – 20 Aug 2026. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one. Nifty 500 history starts 25 Jul 2016, so that benchmark is not plotted over this window — pick a shorter range to see it.
View as table
| Date | Nippon India Pharma Fund |
|---|---|
| 03 Apr 2006 | ₹100.00 |
| 14 Dec 2007 | ₹141.22 |
| 26 Aug 2009 | ₹155.57 |
| 08 May 2011 | ₹264.23 |
| 17 Jan 2013 | ₹331.84 |
| 30 Sep 2014 | ₹588.60 |
| 11 Jun 2016 | ₹629.80 |
| 21 Feb 2018 | ₹666.75 |
| 04 Nov 2019 | ₹725.53 |
| 16 Jul 2021 | ₹1517.55 |
| 28 Mar 2023 | ₹1299.23 |
| 08 Dec 2024 | ₹2503.54 |
| 20 Aug 2026 | ₹2766.31 |
| Metric | Nippon India · Regular NAV ₹571.12 Very High risk ★★★★★ | Category median Sectoral/ Thematic · 252 funds |
|---|---|---|
| +9.96% | +5.83% | |
| +18.01% | +15.63% | |
| +13.48% | +13.23% | |
| +15.00% | +13.85% | |
| +17.69% | +12.26% | |
| +17.28% | — | |
| +20.05% | +15.60% | |
| +18.87% | +14.52% | |
| +17.29% | +13.74% | |
| Risk | ||
| 12.96% | 15.62% | |
| 0.89 | 0.43 | |
| 1.27 | 0.59 | |
| -47.36% | -23.65% | |
| Nifty 500 | — | |
| +7.49% | +3.42% | |
| 0.69 | 0.95 | |
| 102.9% | 105.9% | |
| 66.0% | 93.6% | |
| 1.84% | 2.39% | |
| ₹8,513Cr | ₹1,161Cr | |
| 1.00% | — | |
| None | — | |
| ₹100 | — | |
| ₹5.00K | — | |
| 53% | 45% | |
| Kinjal Desai | — | |
| 03 Apr 2006 | — | |
| 35 | — | |
| 58.1% | — | |
| 2.4% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.